前收市價 | 144.77 |
開市 | 144.98 |
買盤 | 145.72 x 1000 |
賣出價 | 145.70 x 800 |
今日波幅 | 143.13 - 145.80 |
52 週波幅 | 143.13 - 175.97 |
成交量 | |
平均成交量 | 7,452,859 |
市值 | 351.201B |
Beta 值 (5 年,每月) | 0.53 |
市盈率 (最近 12 個月) | 19.62 |
每股盈利 (最近 12 個月) | 7.43 |
業績公佈日 | 2024年7月17日 |
遠期股息及收益率 | 4.96 (3.40%) |
除息日 | 2024年5月20日 |
1 年預測目標價 | 164.19 |
The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the serious risk of T-cell blood cancer in patients who use these therapies. The health regulor has required related updates to other sections of the label such as warnings and precautions, postmarketing experience, patient counseling information and medication guide. In January, the FDA asked a host of drugmakers including Gilead Sciences, Johnson & Johnson and Novartis to add a boxed warning to their CAR-T cancer therapies, as it received reports of patients developing a type of T-cell blood cancer after being treated with them.
A Florida jury on Thursday concluded that Johnson & Johnson's baby powder talc product did not cause the ovarian cancer of a Florida woman who died in 2019. The lawsuit was brought by family members of Patricia Matthey, a Sarasota County resident who used Johnson's baby powder daily from 1965 until August 2016, when she was diagnosed with ovarian cancer, according to her family's lawsuit. J&J's Worldwide Vice President of Litigation Erik Haas said the company was vindicated by the jury's decision.
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Alphabet Inc. (GOOGL) and Johnson & Johnson (JNJ).